Woll, Matthew G. published the artcileDiscovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy, Product Details of C6H9N3, the main research area is survival motor neuron SMN2 splicing modifier spinal muscle atrophy; piperazinylcoumarin preparation structure activity SMN2 splicing modifier muscle atrophy.
The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein. Starting from hits identified in a high-throughput screening campaign and through structure-activity relationship investigations, we have developed small mols. that potently shift the alternative splicing of the SMN2 exon 7, resulting in increased production of the full-length SMN mRNA and protein. Three novel chem. series, represented by compounds 9, 14, and 20, have been optimized to increase the level of SMN protein by >50% in SMA patient-derived fibroblasts at concentrations of <160 nM. Daily administration of these compounds to severe SMA Δ7 mice results in an increased production of SMN protein in disease-relevant tissues and a significant increase in median survival time in a dose-dependent manner. Our work supports the development of an orally administered small mol. for the treatment of patients with SMA. Journal of Medicinal Chemistry published new progress about Drug discovery. 91678-81-8 belongs to class pyrazines, name is 3,5-Dimethylpyrazin-2-amine, and the molecular formula is C6H9N3, Product Details of C6H9N3.